다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Scandinavian journal of infectious diseases, v.33 no.2, 2001년, pp.83 - 96
Calarota, Sandra A. , Wahren, Britta
By eliminating infected cells, virus-specific cytotoxic T-lymphocytes (CTL) play a central role in host protection. Many studies to date seem to support the concept that human immunodeficiency virus (HIV)-specific CTL responses contribute to the control of viral replication, and thus delay the onset of disease. The feasibility of improving the virus-specific T-cell immunity by immunizing during the asymptomatic phase of infection has been studied in man. DNA vaccination is a novel strategy, involving direct inoculation of genetic material that is capable of producing antigen intracellularly for presentation to CTL. Such DNA-based immunization has been shown in animal models to be effective for the induction of both cellular and humoral immune responses as well as for protection from infectious challenge. This article reviews the cell-mediated immune responses in natural HIV-1 infection and the induction by DNA vaccination in humans.
Virus-specific CD8 + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol Borrow P 6103 68 1994
J Virol Koup RA 4650 68 1994 10.1128/JVI.68.7.4650-4655.1994
CD8 + T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc Natl Acad Sci USA Mackewicz CE 2308 92 1995
J Infect Dis Toso JF 964 172 1995 10.1093/infdis/172.4.964
J Exp Med Klein MR 1365 181 1995 10.1084/jem.181.4.1365
J Virol Rinaldo C 5838 69 1995 10.1128/JVI.69.9.5838-5842.1995
Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol van Baalen CA 1913 78 1997
Immunol Lett Rowland-Jones SL 9 66 1999 10.1016/S0165-2478(98)00179-5
Nat Med Koenig S 330 1 1995 10.1038/nm0495-330
T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med Riddell SR 216 2 1996
Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood Lieberman J 2196 90 1997
Nat Med Brodie SJ 34 5 1999 10.1038/4716
Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood Tan R 1506 93 1999
Curr Opin Chem Biol Wahren B 183 1 1997 10.1016/S1367-5931(97)80008-7
Weiner DB. Genetic immunization: a new era in vaccines and immune therapeutics. FASEB J Chattergoon M 753 11 1997
Proc Natl Acad Sci USA Wang B 4156 90 1993 10.1073/pnas.90.9.4156
AIDS Res Hum Retroviruses Fuller DH 1433 10 1994 10.1089/aid.1994.10.1433
Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J Virol Yasutomi Y 678 70 1996
Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet Calarota S 1320 351 1998
J Immunol Calarota SA 2330 163 1999 10.4049/jimmunol.163.4.2330
First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis MacGregor RR 92 178 1998
Enhancement of cellular immune response in HIV-1 seropositive individuals: a DNA-based trial. Clin Immunol Boyer JD 100 90 1999
Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science Wang R 476 282 1998
Eur J Immunol Kägi D 3256 25 1995 10.1002/eji.1830251209
Walker, Bruce D., Chakrabarti, Sekhar, Moss, Bernard, Paradis, Timothy J., Flynn, Theresa, Durno, Amy G., Blumberg, Richard S., Kaplan, Joan C., Hirsch, Martin S., Schooley, Robert T.. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature, vol.328, no.6128, 345-348.
AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature Plata F 348 328 1987
AIDS Walker BD 177 4 1990 10.1097/00002030-199003000-00001
J Immunol Hoffenbach A 452 142 1989 10.4049/jimmunol.142.2.452
Carboxyl-terminal and central regions of human immunodeficiency virus-1 nef recognized by cytotoxic T lymphocytes from lymphoid organs. An in vitro limiting dilution analysis. J Clin Invest Hadida F 53 89 1992
Detection of a vigorous HIV-1-specific cytotoxic T lymphocyte response in cerebrospinal fluid from infected persons with AIDS dementia complex. J Immunol Jassoy C 3113 149 1992
HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell Cheynier R 373 78 1994
J Exp Med Musey L 293 185 1997 10.1084/jem.185.2.293
Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8 + lymphocyte activity. J Infect Dis Ferbas J 329 172 1995
AIDS McMichael AJ S155 8 1 1994
AIDS Lamhamedi-Cherradi S 421 9 1995 10.1097/00002030-199509050-00002
Buseyne F. Cytotoxic T lymphocytes in human immunodeficiency virus infection: regulator genes. Curr Top Microbiol Immunol Riviere Y 65 189 1994 10.1007/978-3-642-78530-6_4
J Virol Littaua RA 608 66 1992 10.1128/JVI.66.1.608-611.1992
Human CD4 + cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine. J Infect Dis Stanhope PE 92 168 1993
Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantification of effector cell populations with p17 and p24 specificities. J Exp Med Koup RA 1593 174 1991
AIDS Lamhamedi-Cherradi S 1249 6 1992 10.1097/00002030-199211000-00002
J Exp Med Caramichael A 249 177 1993 10.1084/jem.177.2.249
Human immunodeficiency virus type 1 (HIV-1)- and Epstein-Barr virus-specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1-infected persons. J Infect Dis Geretti AM 34 174 1996
Science Walker CM 1563 234 1986 10.1126/science.2431484
Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8 + T cells. Immunol Today Levy JA 217 17 1996
J Infect Dis Barker E S485 179 3 1999 10.1086/314808
Identification of RANTES, MIP-1α, and MIP- 1β as the major HIV-suppressive factors produced by CD8 + T cells. Science Cocchi F 1811 270 1995
Lancet Mackewicz CE 1671 344 1994 10.1016/S0140-6736(94)90459-6
Evolution and plasticity of CTL responses against HIV. Curr Opin Immunol Autran B 546 8 1996
An activated CD8 + T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol Landay AL 106 69 1993
J Immunol Luzuriaga K 433 154 1995 10.4049/jimmunol.154.1.433
Adv Immunol Rowland-Jones S 277 65 1997 10.1016/S0065-2776(08)60745-2
Selective in vitro expansion of HLA class I-restricted HIV-1 Gag-specific CD8 + T cells: cytotoxic T-lymphocyte epitopes and precursor frequencies. AIDS van Baalen CA 781 7 1993
A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. AIDS Res Hum Retroviruses Lubaki MN 1427 10 1994
Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol Spector DH 2298 64 1990
Science Lusso P 848 247 1990 10.1126/science.2305256
Proc Natl Acad Sci USA Andäng M 12749 96 1999 10.1073/pnas.96.22.12749
Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infected individuals. Science Altman J 94 274 1996
J Exp Med Lalvani A 859 186 1997 10.1084/jem.186.6.859
Immunity Murali-Krishna K 177 8 1998 10.1016/S1074-7613(00)80470-7
Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods Suni MA 89 212 1998
A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS Larsson M 767 13 1999
Curr Opin Immunol Rowland-Jones SL 448 7 1995 10.1016/0952-7915(95)80087-5
Shearer, Gene M., Clerici, Mario. Protective immunity against HIV infection: has nature done the experiment for us?. Immunology today, vol.17, no.1, 21-24.
Immunol Today Heeney JL 247 20 1999 10.1016/S0167-5699(98)01437-6
J Infect Dis Bernard NF 538 179 1999 10.1086/314621
Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis Goh WC 548 179 1999
Curr Opin Immunol Franco A 524 7 1995 10.1016/0952-7915(95)80098-0
Effects of HIV-1 Tat on expression of HLA class I molecules. J Acquir Immune Defic Syndr Hum Retrovirol Matsui M 233 11 1996 10.1097/00042560-199603010-00003
Nat Med Schwartz O 338 2 1996 10.1038/nm0396-338
J Exp Med Koup RA 779 180 1994 10.1084/jem.180.3.779
Cell McMichael A 673 93 1998 10.1016/S0092-8674(00)81428-2
J Exp Med Couillin I 1129 180 1994 10.1084/jem.180.3.1129
Klenerman, Paul, Rowland-Jones, Sarah, McAdam, Steve, Edwards, Jon, Daenke, Susan, Lalloo, David, Köppe, Britta, Rosenberg, William, Boyd, Diana, Edwards, Anne, Giangrande, Paul, Phillips, Rodney E., McMichael, Andrew J.. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature, vol.369, no.6479, 403-407.
Science Meier U-C 1360 270 1995 10.1126/science.270.5240.1360
Immunol Today Klein MR 317 19 1998 10.1016/S0167-5699(98)01288-2
N Engl J Med Wahren B 393 315 1986
Shearer, Gene M., Clerici, Mario. Early T-helper cell defects in HIV infection :. AIDS, vol.5, no.3, 245-254.
J Virol Wahren B 2017 61 1987 10.1128/JVI.61.6.2017-2023.1987
HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals. Clin Exp Immunol Pontesilli O 419 100 1995
AIDS Res Hum Retroviruses Rosenberg ES S143 14 1998
A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med Redfield RR 1677 324 1991
J Acquir Immune Defic Syndr Hum Retrovirol Kundu SK 26974 15 1997 10.1097/00042560-199708010-00004
Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr Wahren B 220 7 1994
AIDS Leandersson A-C 157 12 1998 10.1097/00002030-199802000-00005
Lancet Sandström E 1735 353 1999 10.1016/S0140-6736(98)06493-9
J Infect Dis Ratto-Kim S 337 179 1999 10.1086/314587
Immunol Today Tighe H 89 19 1998 10.1016/S0167-5699(97)01201-2
Proc Natl Acad Sci USA Fynan EF 11478 90 1993 10.1073/pnas.90.24.11478
Heterologous protection against influenza by injection of DNA encoding a viral protein. Science Ulmer JB 1745 259 1993
Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med Boyer JD 526 3 1997
Genetic immunization is a simple method for eliciting an immune response. Nature Tang D 152 356 1992
Influenza virus nucleoprotein-specific immunoglubulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol Pertmer TM 6119 70 1996
J Immunol Feltquate DM 2278 158 1997 10.4049/jimmunol.158.5.2278
Induction of HIV-1 specific mucosal immune responses by DNA vaccination. Scand J Immunol Asakura Y 326 46 1997
Springer Semin Immunopathol Corr M 139 19 1997 10.1007/BF00870264
Vaccine Robinson HL 785 15 1997 10.1016/S0264-410X(96)00249-6
Mol Med Fu T-M 362 3 1997 10.1007/BF03401683
Adv Exp Med Biol Liu MA 187 452 1998 10.1007/978-1-4615-5355-7_21
J Immunol Corr M 4721 163 1999 10.4049/jimmunol.163.9.4721
Immune responses to the HIV rev regulatory gene. Antibiot Chemother Wahren B 105 48 1996
Theoretical Biology and Biophysics Group. Los Alamos Korber BTM 1998
Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophagetropic and T-lymphotropic HIV-1 strains. J Virol Huang L 8952 72 1998
Mol Cell Biol Kalland K-H 7436 14 1994 10.1128/MCB.14.11.7436
Nat Med Miller RH 389 3 1997 10.1038/nm0497-389
Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation. J Gen Virol Braun R 2965 79 1998
Biogenic Amines Kjerrström A 93 15 1999
Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses. Vaccine Hinkula J 874 15 1997
Proc Natl Acad Sci USA McClements WL 11414 93 1996 10.1073/pnas.93.21.11414
J Virol Robert-Guroff M 3391 64 1990 10.1128/JVI.64.7.3391-3398.1990
Analysis of human immunodeficiency virus type 1 nef gene sequences present in vivo. J Virol Shugars D 4639 67 1993
Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. AIDS Kelleher AD 175 12 1998
Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV disease. Science Autran B 112 277 1997
Long-lasting recovery in CD4 T-cell function and viral load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet Li TS 1682 351 1998
Quantification of HIV-1-specific cytotoxic T lymphocytes and plasma viral load of viral RNA. Science Ogg GS 2103 279 1998
Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol Ogg GS 797 73 1999
Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J Infect Dis Dalod M 61 178 1998
The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis Markowitz M 525 179 1999
J Infect Dis Malhotra U 121 181 2000 10.1086/315202
Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy. Sex Transm Infect Kaufmann GR 218 75 1999
Immunol Lett Pontesilli O 213 66 1999 10.1016/S0165-2478(98)00160-6
J Infect Dis Pontesilli O 76 180 1999 10.1086/314837
Nature Krieg AM 546 374 1995 10.1038/374546a0
CpG motifs as immune adjuvants. Vaccine Klinman DM 19 17 1999
Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science Sato Y 352 273 1996
Nat Med Roman M 849 3 1997 10.1038/nm0897-849
Ann N Y Acad Sci Nichols WW 30 772 1995 10.1111/j.1749-6632.1995.tb44729.x
Hum Gene Ther Martin T 759 10 1999 10.1089/10430349950018517
J Immunol Ertl HCJ 3579 156 1996 10.4049/jimmunol.156.10.3579
Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I Env/Rev vaccine in HIV-infected recipients: follow-up data. J Infect Dis MacGregor RR 181: 406 2000
Frequent infection of peripheral blood CD8-positive T-lymphocytes with HIV-1. Lancet Livingstone WJ 649 348 1996
J Immunol Joly P 2193 143 1989 10.4049/jimmunol.143.7.2193
Eur J Immunol Sadat-Sowti B 737 21 1991 10.1002/eji.1830210329
Curr Opin Immunol Cross-clade Gotch F. 388 10 1998 10.1016/S0952-7915(98)80109-X
J Infect Dis El-Daher N 306 168 1993 10.1093/infdis/168.2.306
J Acquir Immune Defic Syndr Hum Retrovirol Perales M-A 27 10 1995
Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. J Infect Dis Corey L 301 177 1998
J Infect Dis Fleury B 734 174 1996 10.1093/infdis/174.4.734
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS Belshe RB 2407 12 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1 MN gp120, HIV-1 SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis Wright PF 1230 177 1998
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8 + cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis Fast P 290 180 1999
A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS). J Immunol Shearer GM 2514 137 1986
Immunol Today Clerici M 107 14 1993 10.1016/0167-5699(93)90208-3
HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA Clerici M 42 271 1994
Immunology Mathiesen T 453 67 1989
HIV-1 peptides induce a proliferative response in lymphocytes from infected persons. J Acquir Immune Defic Syndr Wahren B 448 2 1989
Cellular and humoral antigenic epitopes in HIV and SIV. Immunology Nixon DF 515 76 1992
Chem Immunol Siliciano RF 127 56 1993 10.1159/000421952
A dose-ranging study of a prototype synthetic HIV-1 MN V3 branched peptide vaccine. J Infect Dis Gorse GJ 330 173 1996
Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J Infect Dis Belshe RB 1387 168 1993
Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. Ann Intern Med Graham BS 270 125 1996
HIV-1 MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1 MN recombinant glycoprotein 120 vaccine. AIDS Res Hum Retroviruses Gorse GJ 115 15 1999
AIDS Res Hum Retroviruses Pialoux G 373 11 1995 10.1089/aid.1995.11.373
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J Infect Dis Graham BS 244 166 1992
Presence at different clinical stages. J Immunol Ljunggren K 2263 139 1987
Anti-HIV-1 ADCC. AIDS Res Hum Retroviruses Tyler DS 557 5 1989 10.1089/aid.1989.5.557
Broadly reactive antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad neutralizing response in human infection. Viral Immunol Koup RA 215 4 1991
Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol Tyler DS 3375 144 1990
Analyses of functional antibody responses in HIV-1-infected individuals after vaccination with rgp160. Clin Diagn Virol Broliden K 115 6 1996
J Virol Yang OO 5799 70 1996 10.1128/JVI.70.9.5799-5806.1996
Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-alpha), and TNF-beta when they encounter their target antigens. J Virol Jassoy C 2844 67 1993
Cytotoxic CD8 + T lymphocytes reactive with human immunodeficiency virus-1 produce granulocyte/macrophage colony-stimulating factor and variable amounts of interleukins 2, 3, and 4 following stimulation with the cognate epitope. Clin Immunol Immunopathol Price P 100 74 1995
Immunol Today Zinkernagel RM 262 15 1994 10.1016/0167-5699(94)90005-1
Induction of HIV-1 replication in a chronically infected T-cell line by cytotoxic T lymphocytes. J Acquir Immune Defic Syndr Harrer T 865 6 1993
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.